LexDanaLexDanabeta
Inventor

Anandan Palani

Inventor
Bridgewater, NJ, US

Overview

62→
Patents
2002–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 62 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations35%
C07DHeterocyclic compounds34%
A61KPreparations for medical, dental or toiletry purposes25%
C07KPeptides2%
Y02ATechnologies for adaptation to climate change2%
C07CAcyclic or carbocyclic compounds1%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%
PatentTitleYear
11,058,775Insulin dimer-incretin conjugates202110,793,615Long-acting co-agonists of the glucagon and GLP-1 receptors202010,493,125Co-agonists of the glucagon and GLP-1 receptors201910,413,593Co-agonists of the glucagon and GLP-1 receptors20199,969,711NK20189,745,324'Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use'20179,688,693'NK1 antagonists'20179,573,939'Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases'20179,549,917'Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases'20179,549,921'Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C'20179,493,461'Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C'20169,469,615'Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators'20169,469,629'NK1 antagonists'20169,364,482'Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases'20169,290,454'Substituted isoquinolines as CRTH2 receptor modulators'20169,290,453'Quinolines and aza-quinolines as CRTH2 receptor modulators'20169,265,773'Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases'20169,242,998'Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C'20169,243,002'Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C'20168,927,559'Quinazolinone-type compounds as CRTH2 antagonists'20158,889,683'Substituted quinoxalines as inhibitors of fatty acid binding protein'20148,809,318'Gamma secretase modulators'20148,796,299'NK1 antagonists'20148,754,216'NK1 antagonists'20148,673,900'Gamma secretase modulators'20148,598,158'Fused tricyclic compounds for the treatment of inflammatory disorders'20138,592,383'Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulators'20138,569,312'Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators'20138,518,975'Gamma secretase modulators'20138,476,274'Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators'20138,450,343'Gamma secretase modulators'20138,426,403'Gamma secretase modulators'20138,426,595'Gamma secretase modulators'20138,357,682'Gamma secretase modulators'20138,324,213'Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators'20128,283,360'Bicyclic heterocyclic derivatives and methods of use thereof'20128,273,895'NK1 antagonists'20128,114,879'Piperazine derivatives useful as CCR5 antagonists'20128,034,933'Piperidine derivatives useful as CCR5 antagonists'20118,026,364'NK1 antagonists'20117,902,366'NK1 antagonists'20117,884,080'Azetidinone derivatives and methods of use thereof'20117,763,623'Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia'20107,750,015'Nitrogen-containing heterocyclic compounds and methods of use thereof'20107,737,155'Nitrogen-containing heterocyclic compounds and methods of use thereof'20107,723,342'Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia'20107,709,641'NK1 antagonists'20107,498,438'Fused ring NK1 antagonists'20097,452,891'MCH antagonists and their use in the treatment of obesity'20087,442,703'Piperidine derivatives useful as CCR5 antagonists'20087,384,948'Piperidine derivatives useful as CCR5 antagonists'20087,384,944'Piperazine derivatives useful as CCR5 antagonists'20087,354,922'Bridged ring NK1 antagonists'20087,348,328'MCH antagonists for the treatment of obesity'20087,345,042'MCH antagonists for the treatment of obesity'20087,049,320'NK1 antagonists'20067,045,636'MCH antagonists for the treatment of obesity'20066,900,329'MCH antagonists and their use in the treatment of obesity'20056,689,765'Piperazine derivatives useful as CCR5 antagonists'20046,602,885'Piperidine derivatives useful as CCR5 antagonists'20036,391,865'Piperazine derivatives useful as CCR5 antagonists'20026,387,930'Piperidine derivatives useful as CCR5 antagonists'2002

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2002–2012Patents assigned to SCHERING CORP (21)· patent assignee history
2002–2008Based in Kenilworth, NJ, US· patent location history
2005–2021Based in Bridgewater, NJ, US· patent location history
2012–2021Patents assigned to MERCK SHARP & DOHME (27)· patent assignee history
2012–2020Patents assigned to PALANI ANANDAN (25)· patent assignee history
2012–2016Patents assigned to HUANG XIANHAI (13)· patent assignee history
2012–2016Patents assigned to ASLANIAN ROBERT G (9)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
MERCK SHARP & DOHME272012–2021
PALANI ANANDANself252012–2020
SCHERING CORP212002–2012
HUANG XIANHAI132012–2016
ASLANIAN ROBERT G92012–2016
Locations
LocationPatentsSpan
Bridgewater, New Jersey, US572005–2021
Kenilworth, New Jersey, US52002–2008